|Day Low/High||46.01 / 47.52|
|52 Wk Low/High||30.79 / 59.89|
Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The firms all have drugs they want the feds to bend the rules to approve.
Materials, financials, cyclicals and health care names tilt the scale to the bullish side.
It's a very boring session with a narrow trading range as investors take break after four days of rally mode to digest Federal Reserve Chair Janet Yellen's latest comments. Some stocks of interest: Barclays moved Las Vegas Sands (LVS) to Overweight ...
Biotech IPOs that have relationships with established drug companies will do better than those going it alone.